Cerenome Reported $1.55 Million in Q3 Gross Billings
Houston-based Cerenome is expanding its diagnostic test coverage ahead of a key January Medicare pricing decision.
Updated on Sept. 30, 2026 in Economic Indicators
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?
Cerenome recorded $1.55 million in unaudited gross billings for its CNSide tests during the third quarter of 2026, marking a period of growth for the Houston-based diagnostic firm. The company billed 222 tests during the quarter as it prepares for an upcoming Medicare coverage milestone.
Why it matters
The company is scaling its test volume and expanding its contracted covered lives to reach an annualized gross billing run rate of $10 million to $12 million by the end of 2026. Securing favorable pricing for its testing code remains a central factor in its revenue stability and market reach.
Cerenome recorded $1.55 million in gross billings for 222 tests in Q3 2026, while targeting an annualized billing run rate of $10 million to $12 million for Q4 2026. The firm currently operates with 158 million contracted covered lives, aiming to reach 200 million by early 2027.
The players
Cerenome
A Houston-based diagnostic company that develops the CNSide testing platform for cancer monitoring.
The details
Gross billings represent charges submitted to payers at list prices for the CNSide platform. Cerenome management calculated these figures using claims submitted through September 30, 2026. To support revenue growth, the company plans to introduce new testing menu items, including breast cancer protein expression assays and a CSF Molecular Profile Test, in the fourth quarter.
Timeline
Q3 2026: The period in which 222 tests were billed for $1.55 million.
Q4 2026: Scheduled launch for the CSF Molecular Profile Test and breast cancer assays.
January 1, 2027: Target effective date for the CMS Medicare pricing decision regarding code 0640U.
Early 2027: Expected milestone of 200 million total covered lives and beneficiaries.
Market Landscape
The firm is navigating the CMS Medicare Proprietary Laboratory Analyses (PLA) coding and pricing process to secure long-term reimbursement for its diagnostic tests. This move follows a typical diagnostic growth cycle where volume scaling must precede or coincide with formal federal price setting.
Operators in the healthcare space should monitor how code 0640U pricing affects future reimbursement rates for similar diagnostic platforms. Tracking these CMS milestones is essential for businesses forecasting revenue models contingent on Medicare coverage.
The takeaway
Cerenome is aggressively scaling its diagnostic test volume as it prepares for a critical Medicare pricing adjustment. Operators should watch for the January 1, 2027, effective date to determine if these coverage milestones shift the standard reimbursement landscape for diagnostic providers.
What happens next
The company expects to reach a target of 200 million covered lives by early 2027 and complete the launch of new testing menu items in Q4 2026.
Further reading
For more on how shifts in healthcare reimbursement impact local business sectors, visit the Economic Indicators section.
More information
For more details on the testing technology, visit the CNSide diagnostic platform information.
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?
